Denufosol tetrasodium
CAS: 318250-11-2
Rif. 3D-ND45968
1mg | 1.096,00 € | ||
2mg | 2.068,00 € | ||
5mg | 3.318,00 € | ||
10mg | 5.401,00 € | ||
500µg | 779,00 € |
Informazioni sul prodotto
- 2'-Deoxycytidine P'''-5'-ester with uridine 5'-(pentahydrogen tetraphosphate) sodium saltUridine 5'-(pentahydrogen tetraphosphate)
- P'5'-ester 2'-deoxycytidineINS 37217[[(3S,5R)-5-(4-Amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyp
- dCp4U
- Ins-37217
- Uridine 5'-(pentahydrogen tetraphosphate) P'''--5'-ester with 2'-deoxycytidine tetrasodium salt
- tetrasodium [[[[(3S,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate
- tetrasodium [[[[(2R,3S,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-oxido-phosphoryl]oxy-oxido-phosphoryl]oxy-oxido-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl phosphate
A P2Y2 receptor agonist that has been studied in cystic fibrosis and retinal diseases such as retinal detachment. Denufosol was studied as an inhaled drug for cystic fibrosis, due to its ability to activate an alternative chloride channel and avoiding the defective CFTR chloride channel. This enhances hydration of the lung mucosa and improves mucociliary clearance. The drug did not progress from phase III clinical trials. Denufosol resulted in subretinal fluid reabsorption in in vivo model of retinal detachment.
Proprietà chimiche
Richiesta tecnica su: 3D-ND45968 Denufosol tetrasodium
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.